Compare KeyCorp (KEY) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs GeneDx Holdings Corp — how do they compare? KeyCorp trades at $19.97 (market cap $21.45B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: KeyCorp is far larger — about 10.6× GeneDx Holdings Corp's market cap, and KeyCorp pays a 4.08% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold KeyCorp for 66 Days and GeneDx Holdings Corp for 19 Days on average.
| KEY | WGS | |
|---|---|---|
Market Cap | $21.45B | $2.02B |
Volume | 19,450,846 | 734,640 |
Sector | Financials | Health |
52-Week High | $23.99 | $167.51 |
52-Week Low | $16.78 | $34.51 |
Typical Hold Time | 66 Days | 19 Days |
Enterprise Value | $34.63B | $2.05B |
Dividend Yield | 4.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $20.10, up 1.36% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 11.75, net income margin of 26.72%, and three consecutive quarterly earnings beats. Recent corporate actions include a dividend payment scheduled for September 2026 and key executive appointments in wealth and retail banking.
The outlook is supported by analyst consensus with a $25.00 price target and 60.79% buy ratings, though risks include volatile cash flows and competitive pressures. Revenue growth momentum and aggressive share buybacks provide upside potential, but investors should weigh the frozen dividend against peers and monitor interest rate impacts on net interest income.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
